Innate Pharma S.A. (the “Company” – Euronext Paris: FR0010331421 – IPH) is a French biotechnology company. It specializes in the discovery, development, and commercialization of first-in-class therapeutic antibodies exploiting the immune system to treat cancers in strong medical need.
Innate Pharma on the Nasdaq Global Market
The company announced on 7 October the launch of its initial public offering on the Nasdaq Global Market. It is part of a capital increase of up to 10,666,666 new shares. In addition, there is an over-allocation option that only certain investors can subscribe to.
Moreover, the company will complete the transaction through an offer of American Depositary Shares (“ADSs”) in the United States. Also through a concurrent private placement of common shares in Europe (including France) and in other countries outside the United States (the “Private Placement” and, together with the ADS Offer, the “Global Offer”).
Innate Pharma follows the path set by DBV Technologies, Cellectis or Genfit.
The Marseille-based biotech company, which specializes in the research and development of innovative immunotherapy drugs for the treatment of cancer, will enter the Nasdaq. Innate Pharma announced the launch of its initial public offering, which will dilute its share capital by more than 14%.
As part of this operation, the French biotech company will create up to 10.666 million new shares. Also, investors specializing in the biotechnology sector will have exclusive access to this subscription.
By increasing its capital, Innate Pharma says it wants to increase its financial flexibility to advance its portfolio of drug candidates. The main focus is the clinical development of the company’s most advanced product candidate, Monalizumab, in collaboration with AstraZeneca.
This is an exemplary agreement that AstraZeneca and the French biotech Innate Pharma just signed. The first collaboration between the two companies was in 2015. This agreement includes several points.
Above all, the British laboratory will exercise, for $100 million, the option he had asked in 2015 on Monalizumab. That is a cancer immunotherapy product based on an original mechanism of action.
The banks in charge of the offer will also have an over-allotment option up to a maximum of 15% of the total number of ADSs and shares issued.
Eric Vivier will fight cancer at Innate Pharma
Euronext values the company at $436 million and with a solid cash position of nearly $241 million. Innate Pharma has succeeded in becoming one of Europe’s leading cancer immunotherapy companies. In addition to its investors, biotech has convinced industrial partners through the quality of its research.
Coming from the Marseille Lumigny Immunology Centre, it has, in addition to the molecules currently in clinical trials, a rich portfolio of preclinical projects and original technological platforms. This will feed the future expansion of the company.
(Featured Image by PIXI1861)
First published in lesechos, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. B2I assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. B2I is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [1xBet Affiliate Program]
Wanna discover one weird sports betting niche with plenty of low-hanging fruit just waiting for you to exploit? Then read...
Which Are the Most Important Fintech News from February 2024
Monite secured $6 million in a top-up financing round, bringing its total seed-stage funding to $16 million. The funds will...
Spanish Pharma Listed Companies Reduce Their Profits by 37% in 2023
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition...
How Much Does Europe Invest in Sustainability
Europe is moving rapidly towards a renewal of the regulatory framework for sustainability , with the obligation for almost 50,000...
The German Medical Cannabis Market Could Be Worth Three Billion
Currently, the German medical cannabis market serves a relatively small part of the population, with approximately 28,000 patients, or less...
Biotech2 weeks ago
Haier Receives Authorization from the Cnmc to Buy 20% of Shanghai Raas from Grifols
Impact Investing4 days ago
Guarantee Fund in Italy Brings Maximum Business Coverage to 5 Million
Biotech1 week ago
Gotham Insists on Projecting Its Doubts on Grifols
Crypto2 days ago
Bitcoin, Soon an ATH of 70,000: Investors also FOMO These 5 Cryptos